Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 7/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904817 | 0.77 | ALDH1A1 (0.62) | ALDH1A1KDM4EMAPTLMNAHTT | |
| SCHEMBL10328047 | 0.76 | SLC9A1 (0.44) | FEN1KAT2BALDH1A1ADORA3ADORA2A | |
| SCHEMBL10328042 | 0.75 | SLC9A1 (0.50) | KDM4ELMNA | |
| SCHEMBL7015479 | 0.73 | KDM4E (0.42) | FEN1KAT2BBRD4ALDH1A1KDM4E | |
| SCHEMBL169123 | 0.73 | FEN1 (0.36) | FEN1KAT2BBRD4MAPTPARP1 | |
| SCHEMBL10328327 | 0.72 | ACVR1 (0.51) | FEN1BRD4IDO1 | |
| SCHEMBL11195631 | 0.70 | MAPT (0.57) | ALDH1A1KDM4EMAPTPARP1LMNA | |
| SCHEMBL10328378 | 0.69 | ALDH1A1 (0.38) | FEN1KAT2BBRD4ALDH1A1ADORA3 | |
| SCHEMBL17950689 | 0.69 | GPR139 (0.45) | KAT2BBRD4KDM4EPARP1LMNA | |
| SCHEMBL10328257 | 0.69 | IDO1 (0.39) | KAT2BALDH1A1IDO1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471006-B2 | Coupling agents for peptide synthesis | UNIVERSITY OF MASSACHUSETTS (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120277428-A1 | NEW COUPLING AGENTS FOR PEPTIDE SYNTHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-8217169-B2 | Coupling agents for peptide synthesis | UNIVERSITY OF MASSACHUSETTS (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110028720-A1 | New Coupling Agents for Peptide Synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-03 | — | — | US | disclosed |
| US-7812158-B2 | Coupling agents for peptide synthesis | UNIVERSITY OF MASSACHUSETTS (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070112196-A1 | New coupling agents for peptide synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277428-A1 | NEW COUPLING AGENTS FOR PEPTIDE SYNTHESIS | NGLY1, NPPA, VIP | FEN1 3367/4885KAT2B 3816/4885BRD4 3205/4885 |
| US-20070112196-A1 | New coupling agents for peptide synthesis | NGLY1, NPPA, VIP | FEN1 3282/4885KAT2B 3874/4885BRD4 3492/4885 |
| US-20110028720-A1 | New Coupling Agents for Peptide Synthesis | NGLY1, NPPA, VIP | FEN1 3367/4885KAT2B 3816/4885BRD4 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.